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Resumo 
 
 
 
Staphylococcus aureus é uma bactéria de Gram-positivo que está 
comumente presente em infeções da pele podendo espalhar-se através da 
corrente sanguínea e afetar outros órgãos. Para o tratamento destas 
infeções são normalmente utilizados os antibióticos, no entanto, os 
microrganismos têm a capacidade de adquirir resistência aos agentes 
antimicrobianos. A terapia fotodinâmica antimicrobiana está a ser 
estudada ativamente como alternativa ao tratamento de infeções 
localizadas. Este estudo foi orientado para avaliar a atividade 
antibacteriana da terapia fotodinâmica no tratamento de infeções por S.  
aureus na superfície da pele. Foi também avaliado o efeito sinérgico da 
terapia fotodinâmica antimicrobiana e de antibióticos (ampicilina, 
cloranfenicol, canamicina, penicilina G e tetraciclina) na inativação de S. 
aureus. Para este fim, foi utilizado uma porfirina tetra catiónica (Tetra-
Py+-Me) que foi testada in vitro para inativar a bactéria numa solução 
tampão e ex vivo em pele de porco artificialmente contaminada com S. 
aureus. Os resultados mostraram inactivação eficaz de S. aureus (redução 
de 8 log) em tampão fosfato salino utilizando a porfirina Tetra-Py+-Me 
numa concentração de 5.0 µM após 180 minutos de irradiação com luz 
branca (com incidência de 40 W.m-2) Na combinação de ampicilina (MIC 
0,25 µg mL-1) em concentrações de 0,5 µg mL-1 e 1 µg mL-1 com a 
porfirina Tetra-Py+-Me a 5.0 µM (em tampão fosfato salino) foi observado 
um decréscimo mais rápido (8 log) na inativação total do número de 
bactérias após 30 e 60 min de irradiação, respetivamente. Para os outros 
antibióticos não foi observado qualquer aumento na inactivação 
bacteriana. Nos ensaios ex vivo houve uma redução de ~4 log após 
tratamento com a porfirina Tetra-Py+-Me a 50 µM após 180 minutos de 
irradiação. A eficiência da inativação na pele nas mesmas condições, mas 
na presença de 5 μg mL-1 de ampicilina foi significativamente diferente da 
obtida com PS na ausência do antibiótico com uma inativação de ~5,6 log.  
Os resultados deste estudo mostraram que a DPT é uma abordagem eficaz 
para controlar infeções por S. aureus na pele, inativando as bactérias até 
ao limite de deteção após três ciclos de tratamento. Além disso, a 
combinação de aPDT com antibióticos pode aumentar a eficácia da 
inactivação bacteriana, permitindo a redução do tempo de tratamento para 
um quarto. 
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Abstract 
 
 
 
Staphylococcus aureus is a Gram-positive bacterium common in skin 
infections, but this bacterium can spread through the bloodstream and 
infect distant organs. To the treatment of this infections antibiotics are 
usually used, however, microorganisms have acquired the capacity to 
develop resistance against antimicrobial agents. Antimicrobial 
photodynamic therapy (aPDT) is being actively studied as a possible 
alternative to antibiotics to treat localized infections. This study was 
conducted to evaluate the antibacterial activity of aPDT for treatment of 
S. aureus infections on skin. The synergistic effect of aPDT and antibiotics 
(ampicillin, chloramphenicol, kanamycin, penicillin G and tetracycline) to 
inactivate S. aureus was also evaluated. To this purpose, a tetracationic 
porphyrin, the 5,10,15,20-tetrakis(1-methylpiridinium-4-yl)porphyrin 
tetra-iodide (Tetra-Py+-Me) was used to inactivate S. aureus in vitro using 
a buffer solution (PBS) and ex vivo, on pork skin artificially contamined 
with S. aureus. The results show an efficient inactivation of S. aureus in 
PBS using 5.0 μM of Tetra-Py+-Me during 180 min in the presence of a 
white light at an irradiance of 40 W m-2 (reduction of 8 log). When aPDT 
was done in the presence of ampicillin at 0.5 and 1.0 μg mL-1 (MIC dose 
0.25 μg mL) in PBS a faster decrease (8 log) in total bacterial number was 
observed at 60 and 30 min, respectively. For the other antibiotics no 
increase in bacterial inactivation was observed. In ex vivo experiments a 
reduction of ~4 log of S. aureus after treatment with 50 µM of Tetra-Py+-
Me under after 180 min. The efficiency of inactivation in the skin in the 
same conditions but in the presence of 5 μg mL-1 of ampicillin at 50 µM 
was significantly different of that obtained with PS in the absence of 
antibiotic with an inactivation of ~5.6 log. The results of this study showed 
that aPDT is an effective approache to control S. aureus infection in skin, 
inactivating the bacteria to the detection limit after three cycles of 
treatment. Moreover, the combination of aPDT with antibiotics can 
increase the efficacy of bacterial inactivation, allowing the reduction the 
treatment time for a quarter. 
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THESIS OUTLINE 
 
 
The objective of this study was to evaluate the antibacterial activity of aPDT for the 
treatment of Staphylococcus aureus infections on skin and also to assess if aPDT efficacy 
increase in the presence of antibiotics. 
 
For this, the photodynamic effect on S. aureus using a tetracationic porphyrin as 
photosensitizer (PS) Tetra-Py+-Me at different concentration (5.0 µM, 25 µM, 40 µM, 50 
µM) and two artificial white light of irradiances of 40 W m-2 and 150 W m-2) was evaluated. 
The photodynamic inactivation was evaluated in vitro and ex vivo. The assay in ex vivo was 
produced on skin of porcine, which has served as a model for human tissuet. The efficiency 
of photodynamic therapy combinated with different antibiotics (ampicillin, 
chloramphenicol, kanamycin, penicillin G and tetracycline) was also tested in the same 
conditions.  
 
Chapter 1 consists on a brief background, focusing on the photodynamic therapy, the 
antimicrobial photodynamic therapy, the mechanisms of photodynamic inactivation, types 
of antibiotics used for treatment of infections by S. aureus and some mechanisms of 
resistance of antibiotics. 
 
Chapter 2 describes the experimental work, the results obtained and their discussion as well 
as the main conclusions. 
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CHAPTER 1 
 
1. Photodynamic Therapy 
 
1.1. Briefly History 
 
The benefits, for restoration of health, of exposure to sunlight was known in centuries 
[1,2] and it association with photosensitizers has been used for centuries from the ancient 
civilizations of Egypt, Greece and India. In fact, they used the photodynamic action by the 
ingestion of plants containing for instance psoralens which in combination with the exposure 
to sunlight treated skin disorders such as vitiligo, psoriasis and rickets [3,4].  
With the understanding of the photodynamic mechanism, von Tappeiner and 
colleagues performed the first PDT trial in patients with skin carcinoma using eosin as 
photosensitizer (PS), applied topically together with the application of sunlight [3,5].  
The success of this and other tests conducted, in 1993 in Canada, the semi-purified 
preparation of HpD known as the Photofrin® (porfimer sodium), to be the first regulatory 
approval PS for the treatment of bladder cancer. This was later, in 1995, approved by the 
Food and Drug Administration (FDA) for the treatment of esophageal cancer, and later to be 
used in several countries in Europe. Today, there are already several PS approved in several 
countries for applications in PDT [1,5,6]. The PDT, appears in the past years as a viable 
alternative, cost efficient and with promising applications in several areas, namely, as an 
antimicrobial approach, in clinical field, food industry and environmental control [7,8]. 
 
 
1.2. Principle and mechanisms of Photodynamic Therapy 
 
Photodynamic therapy is a therapeutic modality requiring the combined action of 
three main components in promoting cytotoxicity: a PS, a visible light source (a coherent 
laser light or a non-coherent one, for instance, an LED or Xenon lamp), and the molecular 
oxygen usually present in the biological target at an affordable concentration [9]. PDT is 
based on the visible light activation of a PS molecule in the presence of molecular oxygen 
which results in generation of reactive oxygen species (ROS) [10–12]. 
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Reactive oxygen species (ROS) is a collective term used for oxygen derived free radicals 
(superoxide, hydroxyl radical, nitric oxide) and non-radical oxygen derivatives of high 
reactivity (singlet oxygen, hydrogen peroxide, peroxynitrite, hypochlorite) [13,14]. The 
mechanisms of photosensitization involve generation of singlet oxygen (1O2) via energy 
transfer from the triplet excited state of PS to the molecular oxygen which is always abundant 
in a biological environment (Type II) or via electron or hydrogen transfer from the triplet 
excited state of PS to surrounding molecules (Type I) [15–18]. The photophysical process is 
illustrated in Figure 1, using the energy levels or Jablonski diagram, illustrated the states 
according to their energy as well as spin multiplicity [16].  
  
 
 
Figure 1 – Scheme of photosensitization [14]. 
 
One essential property of a good PS is a high intersystem crossing (ISC) yield, a high 
probability of transition from S1 to an excited triplet state T1 [17]. The excited triplet state is 
the main mediator of the photodynamic reactions. In the T1 state, the photosensitizer can 
transfer energy to molecular oxygen (3O2), exciting it to its highly reactive singlet state (
1O2). 
During the energy transfer process the PS is simultaneously brought back to its singlet 
ground state (S0) where it can, in principle, take part in further sensitisation cycles [16,17].  
The basic protocol of PDT involves PS administration followed by a wait time of 
varying duration to allow for the accumulation of the PS in the cells/tissue, after which the 
target tissue is irradiated with light [11,19]. The irradiation activates the PS in singlet ground 
state (S0) to transit from a low power state into a singlet excited state (S1). In this case, there 
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are a transit of electrons to a different orbital, exciting the PS to the form of an unstable 
molecule with a short half-life (first excited singlet-state, S1) [17,20]. In order to return to its 
stable ground state, the PS emits fluorescence or phosphorescence [21]. Fluorescence 
emission does not alter the electron spin but phosphorescence changes [10]. In other hand, 
the unstable molecule can transit to triplet state (T1) and transfers energy with the production 
of ROS as it was mentioned before. 
In aPDT, the high levels of ROS, surrounding pathogenic microorganisms lead to 
cellular damage, specifically oxidate lipids, peptides or nucleic acids [10,22]. Those can 
elicit either cell survival or dead depending on severity and duration of exposure [10,23,24]. 
These radicals reduces the probability of the selection of resistant strains, which is the main 
problem faced by the current conventional antibacterial therapies [25–29] . 
1.3. Light Source  
The efficiency of PDT requires an adequate light that activates the used PS. This light 
must be monochrome and centered on PS absorption band used [30]. The first light sources 
to be used were conventional bulbs with no coherent and polychromatic light [31]. Since the 
emergence of the first laser equipment and LEDs, those light sources have been more used 
in PDT due to its properties: high concentration of energy, low energy dispersion, coherence 
and monochromaticity, possibility of lighting a medium composed of different materials and 
only interaction with a particular component (selectivity) [32]. The wavelength of light used 
for PDT is typically in the wavelength range between 600–800 nm, the so called “therapeutic 
window” which corresponds to a depth of light penetration 0.5 to 1.5 cm [17]. 
The dosimetry of light is a major factor in the effectiveness of treatment and depends 
on the area and depth of the lesion [33]. This parameter is usually expressed by the light 
irradiance, which is defined in terms of energy incident on a given area of lesion per unit 
time (W.m-2, W=J.s-1) [34]. 
The clinical efficacy of PDT dosimetry will also depends on illuminated system used: 
the total dose and irradiation time delivery mode (continuous or fractionated irradiation) 
[35]. The use of optical fibers allowed the light to be directed easily to deliver irradiation to 
desired regions without the requirement of a straight light path [17]. 
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1.4. Photosensitizers (PS) 
PS are usually aromatic molecules that can be a natural or a synthetic nature which 
may absorb light of certain energy and may undergo an electronic transition to the singlet 
excited state (electron spins paired) after interaction with an appropriate light [35]. Different 
PSs have different wavelength range of maximum efficiency, as it is demonstrated in Table 
1. 
 
Table 1 - Photosensitizer  wavelength absorbance maxima in PBS (adapted from Wainwright 1998) [36]. 
Photosensitizer Type 
Wavelength range absorbance 
maximum in buffer solution (nm) 
Psoralen 300-380 
Porphyrin 400-450 
Acridine 400-500 
Phenazine 500-550 
Cyanine 500-600 
Perylenequinonoid 600-650 
Phenothiazinium 620-660 
Phthalocyanine 660-700 
 
 
Depending on its molecular structure and environment, the molecule may then lose 
its energy by electronic or physical processes, thus returning to the ground state, or it may 
undergo a transition to the triplet excited state (electron spins unpaired) which may then react 
further by one or both of two pathways already known as the type I and type II 
photoprocesses [1,36]. This gives rise to activated species which are very reactive towards 
the chemical environment thus producing molecular damages on important biological targets 
[36–38]. Typically, these compounds do not persist in the environment for long periods of 
time [39,40]. 
A photosensitizing agent with potentially optimal properties should be endowed with 
specific features, in addition to the expected photophysical characteristics such as a high 
quantum yield for the generation of both the long-lived triplet state and the cytotoxic singlet 
oxygen species [32]. 
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Such features include [41–44]:  
 a good absorption capacity at the wavelength of the spectral region where the 
light source is emitted and a good efficiency to generate ROS; 
 broad spectrum of action, since one PS can act on bacteria, fungi, yeasts and 
parasitic protozoa;  
 efficacy independent of the antibiotic resistance pattern of the given microbial 
strain;  
 possibility to develop photodynamic protocols which lead to an extensive 
reduction in pathogen population with very limited damage to the host tissue;  
 Cell inactivation provide a mechanism that makes minimum the risk of 
developing resistant strains and mutagenic processes; 
 availability of formulations allowing a ready and specific delivery of the PS 
to the infected area;  
 adequate solubility in body fluids, which affects the transport and the 
retention time; 
 can be used in low concentrations and necessity to use of low cost light 
sources for activation of the photosensitizing agent; 
 Be a low energetic toxic compounds and not suffer degradation by light. 
 
In summary, the photodynamic activity of the PS to induce cell damage or death is 
determined by an overall lipophilicity and ionization of the photoreactive PS; quantum yield 
of the triplet state formation; redox potentials of the excited states (singlet and triplet) of the 
PS, if the reaction follows the type I pathway or the type II; the molecular extinction 
coefficient e and the quantum yield of the singlet oxygen generation, if the reaction occurs 
by the type II pathway [45]. 
A large number of different PS with photodynamic activity are now available and 
they are generally classified as porphyrins or non-porphyrins as described in Table 2.  
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Table 2 - Classification of photosensitizers as porphyrin-like or nonporphyrin-like molecules (adapted from O’Connor et al, 2009) [41]. 
 
Compound Type 
 
Trade name 
 
 
Photosensitizers 
Porphyrin-like 
 Hematoporphyrin 
 
 
Hematoporphyrin derivative 
(Photofrin®) 
 
1
st G
en
er
a
tio
n
 
P
h
o
to
sen
sitizer
s 
 
Metalloporphyrins Lutrin® 
2
n
d  
G
en
er
a
tio
n
 
P
h
o
to
sen
sitizer
s 
Porphycenes  
Pheophorbides Tookad® 
Purpurins  
Clorins 
 
NPe6 
Foscan® 
Phthalocyanines Photosens® 
  
Photosensitizers 
Non-porphyrin-like 
 
Psoralens   
Anthracyclines  
Chalcogenopyrylium dyes  
ADPMs ADPM derivatives 
Cyanines Merocyanine 540 
Cationic cyanines 
Phenothiazinium dyes Methylene Blue 
Toluidine Bue 
Nile Blue 
Pro-drug 5-ALA 
 
Levulan® 
 
Metvix® 
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Porphyrin-derived PSs are further classified as first, second or third generation PSs. 
Porphyrins known from cancer photodynamic therapy were also used to kill bacteria [39].  
Porphyrins are present in nature and they are essential in biochemical processes such 
as in oxygen transport and photosynthesis. Molecules, such as haemoglobin, myoglobin, 
cytochromes, chlorophylls and vitamin B, are part of the porphyrinic compounds [46]. 
Porphyrins are a class of aromatic heterocyclic compounds PS comprise of four pyrrole type 
subunits linked together by four methine bridges that forming a tetrapyrrole ring structure. 
Tetrapyrroles are naturally occurring pigments and one benefit of these compounds is that 
they don’t react with other compounds and they are quenching naturally in a normal 
environment [20]. Accordingly, the tetrapyrrole macrocycle nucleous structure is named 
porphin and its derivatives are named porphyrins. Porphyrins can be transformed into 
cationic entities through the insertion of positively charged substituents in the peripheral 
positions of the tetrapyrrolic macrocycle that affect the kinetics and extent of binding with 
microbial cells [41]. 
A porphyrin skeleton is essentially hydrophobic, so this factor affecting the 
preferential accumulation in cellular hydrophobic loci since such molecules must be able to 
get into cells by crossing lipid membranes [20,47]. Structure activity relationship studies 
suggest that amphiphilic derivatives (as tetracationic porphyrins) exhibit the greatest affinity 
for Gram (+) [26,38,48]. Some studies revealed that tetracationic porphyrins are efficient PS 
against both Gram (+) and Gram (-) bacteria on visible light [35,49].  
First generation PSs are based on naturally porphyrins, such as hematoporphyrin 
(Hp) that is an endogenous porphyrin and is formed from acid hydrolysis of hemoglobin. Its 
derivative, hematoporphyrin derivative (HpD), gave rise to the first PS to be approved for 
use in PDT for treatment of cancer marketed by the name of Photofrin® [32,33].  
This PS remains the most widely used and studied, but have several drawbacks, such 
as contamination with impurities, relatively low absorbance at 630 nm, where tissue 
penetration of light is not optimal, and prolonged skin photosensitivity lasting up to 6–8 
weeks [41]. 
A number of second generation PSs have been developed to prevent certain problems 
associated with the first generation molecules such as prolonged skin photosensitization and 
suboptimal tissue penetration [37]. These PS are chemically pure compared with first 
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generation compounds, absorb light at a longer wavelength and cause significantly less skin 
photosensitization post-treatment [41].  
 Among the second generation of PS are the chlorins, the phthalocyanines, the 
metalloporphyrins and others identified in the Table 2. Chlorins are reduced porphyrins 
characterized by a strong enhancement of the far-red absorption band compared to metal-
free porphyrins. The meso-tetraarylchlorin derivative 5,10,15,20-tetrakis(3-
hydroxyphenyl)chlorin (mTHPC) is a hydrophilic chlorin derivative, which has the trade 
name Foscan® that was approved in 2001 in the European Union (EU) for the palliative 
treatment of head and neck cancer [1,42]. 
 Phthalocyanines has been tested as alternatives for porphyrin and chlorin derivatives. 
Aluminum phthalocyanine sulfonate (AlPcS, Photosens®) is used routinely in Russia for 
PDT [41]. 
 Still within the second generation are endogenous PS that are found in the body, like 
the protoporphyrin IX (PpIX) [31]. PpIX is an intermediate of heme synthesis. In the 
biosynthetic pathway of heme, the 5-aminolevulinic acid (ALA), is the biosynthetic 
precursor of all porphyrins in nature [50]. ALA is not a PS itself, but induces in vivo 
biosynthesis of endogenous porphyrins. ALA is normally formed from the reactants glycine 
and succinyl-coenzyme A in the mitochondria and is then converted into the PS-PpIX [51]. 
Normally, the synthesis of endogenous porphyrins is limited by the presence of free heme, 
but exogenous ALA bypasses this negative feedback control. The trade name of ALA is 
Levulan® and this compound was approved in 1999 for the treatment of actinic keratoses on 
the face and scalp. Studies have shown that its penetrates the skin when topically applied, 
however, its penetration into and nodular tumors is quite limited [50,51]. 
 In an attempt to solve the problem of ALA hydrophilicity and hence their difficult to 
cell penetration, have been developed alkyl esters of ALA, the metilaminolevulinato (MAL), 
which presents as a trade name Metvix®. It was approved in the EU in 2001 for the topical 
treatment of actinic keratosis and Bowen's disease. MAL has a higher lipophilicity and are 
able to penetrate the cell more easily [52,53]. 
The third generation emerged when bound the second generation PSs with antibodies 
and liposomes for selective accumulation within tissue/cells/microorganisms and currently 
represent an active research area in the field [54].  
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Although the majority of PSs at the preclinical stage are porphyrin derivatives, a 
diverse number of non-porphyrin PSs also exist. First of all, the synthetic non-porphyrin 
compounds have demonstrated photosensitizing ability, like the phenothiazine dyes: 
methylene blue and toluidine blue [43,55]. Another group of dyes belongs to the naturally 
occurring PS. Psoralens (furanocoumarins) and perylenequinonoids are two examples of 
natural products which originally act in plants as chemical defence substances against 
microbial or eukaryotic organisms [45]. Significant effort is now being employed in the 
synthesis of pure chemical derivatives with improved activity and minimal side effects [43].  
It would be desirable to have an effective PS for microbial inactivation without the 
need of additional chemicals, which ensures that it will bind preferentially to microbial cells 
instead of mammalian cells [32,52]. An important step forward in this direction was 
prompted by the discovery that PS that are positively charged at physiological pH values 
such as phenothiazines, phthalocyanines and porphyrins can directly promote the 
photoinactivation of both Gram (+) and Gram (-) bacteria [43,44]. Another important 
characteristic during the design of a PS for PDT is their water solubility where must have 
hydrophilic and hydrophobic characteristics, because they must be administrated in a 
solution, but on the other hand they must be able to cross the bacterial cell wall [56]. On the 
other hand, must have a positive charge being extremely important in gram-negative bacteria 
inactivation since their membrane structure excludes many anionic and uncharged lipophilic 
molecules that would lead to phototoxicity [14,35].  
While phenothiazine derivatives are naturally cationic, owing to the involvement of 
one amino group in the π electron cloud resonance, porphyrins and phthalocyanines can be 
transformed into cationic entities trough the insertion of positively charged substituents in 
the peripheral positions of the tetrapyrrolic macrocycle (meso positions) and, respectively, 
tetraazaisoindole macrocycle, which may largely affect the kinetics and extent of binding 
with microbial [25,35,57]. 
The PS more frequently tested in microbial photoinactivation are based mainly in 
meso-substituted tetracationic porphyrins (Figure 2). The popularity of this type of PS results 
from their easy synthesis and potentiality toward further elaboration [43]. In fact, the 
synthetic approaches usually involve the condensation of pyrrole with adequate aldehydes, 
which are available in a wide range, providing porphyrins with different aryl or heteroaryl 
substituents at the meso-positions. Further manipulations of those substituents can give 
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access to a high number of porphyrins that can be designed for the desired application 
[40,43]. 
 
 
Figure 2- Example of structure of one cationic porphyrin derivative [58] 
 
Some bacteria are also known to produce endogenous porphyrins [56]. A few studies 
revealed that bacteria that produce reasonable amounts of endogenous porphyrins can be 
efficiently degraded by photosensitization, since there is no need of break through cell 
barriers [59]. 
Therefore, porphyrins and their derivatives have been reported as one of the most 
promising compounds used in aPDT [46,58,60]. Porphyrins are currently used in PDT due 
to their unique physico-chemical properties, particularly in the treatment of superficial 
cancer; topical treatment of dermatological problems, such as psoriasis, acne, and Bowen’s 
disease; gastrointestinal cancer; age related macular degeneration; cutaneous leishmaniasis; 
and viral infections, such as papillomatosis [42,61,62] and in the photoinactivation of 
microorganisms [23,43].  
 
 
1.5. Antimicrobial Photodynamic Therapy (aPDT)  
 
Antimicrobial Photodynamic Therapy (aPDT) has emerged as a potential alternative 
to antibiotics to treat microbial infections [28]. Membrane permeability barriers, differences 
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in antioxidant enzymes or DNA repair mechanisms and the size of the microbial cell are 
among the factors that affect the photoinactivation process. These factors are described as: 
 
 Bacterial target: Microbial cells display a large variety of size, sub-cellular 
architecture and biochemical composition [63]. The susceptibility to 
photoinactivation processes can be significantly different for the various 
microorganisms [64]. Gram-positive bacteria have an outer wall, which is 
separated from the plasma membrane by a periplasmic space. Once that in their 
wall can be diffused macromolecules with molecular weight up to 60000 Da, and 
the most common PS have in generally a molecular weight of 1500 Da, these can 
cross the outer wall and localize in the immediate surroundings of the 
photosensitive endocellular sites [35]. So, the Gram (+) bacteria are relatively easy 
to kill by PDT, while Gram (-) bacteria show significant resistance [64]. On the 
contrary, the outer wall of Gram(-) bacteria possesses an additional structural 
element, which is external to the peptidoglycan network consisting of a 
glycocalyx, lipolysaccharide, outer membrane lipid bilayer, periplasm, 
peptidoglycan cell wall, and plasma membrane lipid bilayer [64]. This barrier 
keeps out most PS therefore specific methods have to be adopted to ensure that 
the PS can penetrate the bacterium [48].  
 Physiological state: When the cells are in the logarithmic phase of growth are 
more susceptible to photodynamic inactivation than the corresponding cells in the 
stationary phase [63].  
 Cell density: The cell density influence the competition for binding with the 
available PS, as well as for reaction with photogenerated cytotoxic species [65].  
 
In general, the positively charged PS bound to the negatively charged surface of 
bacteria (Gram + and Gram −) can cause damage to bacteria by two mechanisms: DNA 
damage and damage to the cytoplasmic membrane, allowing inactivation of membrane 
transport systems and enzymes or leakage of cellular contents [66,67]. 
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1.5.1. Advantages and disadvantages of antimicrobial photodynamic therapy 
Antimicrobial photodynamic therapy as other type of therapies includes advantages 
and disadvantages. Below (Table 3) are described the most significant 
advantages/disadvantages of the treatment by aPDT. 
 
Table 3 – Same advantages and disadvantages of aPDT [16,20,41,48,68]. 
 Advantages Disadvantages 
 Non-invasive; 
 Selective: targeted to select part of 
organism/tissues (does not influence 
on whole organism); 
 Few side effects; 
 Can be combined with other 
conventional treatments; 
 Equally effective at killing both 
multi-drug resistant microbes as well 
as native bacterial strains; 
 The effect of aPDT on 
microorganisms is much more rapid 
as compared to that of other 
antimicrobial agentes; 
 Does not damage the tissues, in 
particular tissue elements such as 
collagen and elastin in skin; 
 Not generating specific mechanisms 
of resistance. 
 
 Difficulty to obtain the ideal PS with 
all of the adequate characteristics; 
 The lack of highly effective 
antimicrobial clinically approved PSs; 
 New PSs have not yet to be subjected 
to the rigorous and costly 
toxicological and safety studies 
necessary for approval for human use; 
 Treatment may be associated with 
pain; 
 Cutaneous photosensitivity is 
common; 
 Occasional blistering may occur and 
hyperpigmentation can occur at 
treated sites; 
 Located: PDT can only treat areas 
where light can reach. 
 PDT can’t be used in people who 
have certain blood diseases, such as 
any of the porphyrias or people who 
are allergic to porphyrins. 
 
 
 
 
1.5.2. Antimicrobial Photodynamic Therapy of Staphylococcus aureus 
 
Staphylococcus aureus is an important human pathogen and a common etiological 
factor of health care associated as well as community acquired infections [69]. The ability 
of S. aureus to develop multidrug resistance is well documented, so it is crucial to find 
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alternative antimicrobial treatment to which this bacterium [70,71]. A potential alternative 
can be the aPDT to inactivate microbial cells [19,21,72,73]. 
S. aureus is a versatile opportunistic pathogen that is responsible for a wide variety 
of conditions, ranging from superficial skin infections to severe, invasive diseases [74,75]. 
S. aureus skin infections are very contagious, including the following [75–77]: 
 Folliculitis is the least serious. A hair root (follicle) is infected, causing a slightly 
painful, tiny pimple at the base of a hair. 
 Impetigo consists of shallow, fluid-filled blisters that rupture, leaving honey-
colored crusts. Impetigo may itch or hurt. 
 Abscesses (boils or furuncles) are warm, painful collections of pus just below 
the skin. 
 Cellulitis is infection of skin and the tissue just under it. Cellulitis spreads, causing 
pain and redness. 
 Toxic epidermal necrolysis and, in newborns, scalded skin syndrome are 
serious infections. Both lead to large-scale peeling of skin. 
 Necrotizing fasciitis is a severe, rare, potentially lethal soft tissue infection that 
develops in the scrotum and perineum, the abdominal wall, or the extremities. 
 
The use of antibiotics is yet the first treatment option to treat and sometimes to 
eradicate diseases caused by S. aureus [28,78]. An example of treatment could be the use of 
penicillin regardless of strain, now many of its strains are resistant to beta-lactams, 
macrolides, and even vancomycin, the ‘‘drug of last resort’’[70,79]. Methicillin-resistant 
(MRSA) and vancomycin resistant S. aureus (VRSA) are collectively recognized as a very 
serious health threat [8,80]. 
In vitro studies have shown that S. aureus is sensitive to porphyrins, phthalocyanines 
and others PS. Some of these studies are summarized in Table 4.  
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Table 4 – Summary of some studies demonstrating the effect of different PDT conditions on S. aureus survival in vitro, ex vivo and in vivo. 
Article Title PS 
Total light dose 
 
Results 
In vitro 
Bartolomeu, 
2016 [81] 
Effect of Photodynamic Therapy on the 
Virulence Factors of Staphylococcus aureus. 
5,10,15,20-tetrakis(1-
methylpyridinium-4-yl)porphyrin 
tetra-iodide (Tetra-Py+-Me) - 5.0 µM 
40 W/m2 Reduction of 5 log CFU mL-
1 
Almeida, 
2014 [82] 
Photodynamic inactivation of multidrug-
resistant bacteria in hospital wastewaters: 
influence of residual. 
5,10,15,20-tetrakis(1-
methylpyridinium-4-yl)porphyrin 
tetra-iodide (Tetra-Py+-Me) - 5.0 µM 
40 W/m2 reduction of 4 – 5 log CFU 
mL-1 
Mai, 2016 
[29] 
The Antibacterial Effect of Sinoporphyrin 
Sodium Photodynamic Therapy on 
Staphylococcus aureus Planktonic and Biofilm 
Cultures. 
Sinoporphyrin sodium (DVDMS) –  
2 µM 
10 J/cm2 ≥ 90% of the bacteria were 
eradicated 
Sinoporphyrin sodium (DVDMS) – 
5µM 
100 J/cm2 Reduction of 4 log CFU mL-
1 
Hsieh, 2014 
[83] 
5-Aminolevulinic acid induced photodynamic 
inactivation on Staphylococcus aureus and 
Pseudomonas aeruginosa 
5-aminolevulinic acid 
(ALA) – 1 mM 
162 J/cm2 90% of the bacteria were 
eradicated 
Ex vivo 
Lambrechts, 
2005 [11] 
Photodynamic therapy for Staphylococcus 
aureus infected burn wounds in mice. 
meso-mono-phenyl-tri(N-methyl-4-
pyridyl)-porphyrin (PTMPP) 
(Tri-Py+-Me-Ph)- 500 µM 
210 J/cm2 
 
98% of the bacteria were 
eradicated 
Maisch, 
2007 [84] 
Determination of the antibacterial efficacy of a 
new porphyrin-based photosensitizer against 
MRSA ex vivo 
XF-73 (exeporfinium chloride) – 10 
µM 
210 J/cm2 
 
Reduction of ≈ 3.5 log CFU 
mL-1 
In vivo 
Zolfaghari, 
2009 [85] 
In vivo killing of Staphylococcus aureus 
using a light-activated antimicrobial agent 
Methylene Blue (MB) – 100 µg/mL 360 J/cm2 
Reduction of ≈ 1.5 log CFU 
mL-1 
Grinholc, 
2015 [86] 
Antimicrobial photodynamic therapy with 
fulleropyrrolidine: photoinactivation 
mechanism of Staphylococcus aureus, in vitro 
and in vivo studies 
N- mthylpyrrolidimium fullerene 
iodide - 30 µM 
500 W/m2 
Reduction of  2 log CFU 
mL-1 
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Because the delivery of visible light to living tissue is almost by definition a localized 
process, PDT for infections is likely to be applied exclusively to localized disease, as 
opposed to systemic infections such as bacteremia [11].  
 
 
2.  Antibiotics  
 
Antibiotics are derived from three sources: moulds or fungi; bacteria; or synthetic or 
semi-synthetic compounds [87]. They can be used either internally or topically, and their 
function is to either inhibit the growth of pathogens or to kill them [88]. Antibiotics 
represents one of the most revolutionary progresses made in scientific medicine to destroy 
selectively microorganisms, resulting in the treatment and sometimes complete eradication 
of earlier incurable diseases [28,89].  
It might have been supposed that at the beginning of the twenty first century, 
microbiologically-based diseases would have been reduced to a level that no longer had a 
serious impact on human health [88]. There are various antibiotics available and they come 
in various different brand names [87]. Antibiotics are usually grouped together based on how 
they work [71]. Each type of antibiotic only works against certain types of bacterium [28]. 
This is why different antibiotics are used to treat different types of infection [89]. Some 
antibiotics was referred and illustrated in the figure 3.  
 
 
Figure 3 – Structures of some antibiotics. 
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2.1. Penicillin’s - β-lactam antibiotics 
 
  
The β-lactam antibiotics include a number of drugs with a chemical structure and a 
common mechanism of action. In fact, this class of antibiotics has a β-lactam ring which 
may be fused or linked with cyclic non-cyclic radical structures [70,71]. These antibiotics 
inhibit the peptidoglycan synthesis of the bacterial wall [78].The integrity of the β-lactam 
ring is essential for exercise the antibiotic activity. Some bacteria produce enzymes, the β-
lactamases, that opening the β-lactam ring and completely nullifies the antibiotic action [90]. 
The penicillin’s can be classified according to their antibacterial activity [70]: Natural 
penicillin’s; aminopenicillins and others. 
 
 
 
2.1.1. Natural penicillin’s 
 
 
 The benzylpenicillin (penicillin G) are a natural penicillin that currently are use in 
clinical practice [78,91]. Currently, a growing emergency producing bacterial strains that 
produces β-lactamases (resistant to penicillins), led to the need for administered this 
antibiotic with the combination with inactivators of β-lactamases [71]. The action of 
benzylpenicillin on aerobic gram-positive cocci as Staphylococcus spp. are efficient when 
this specie is sensitive, because do not produce beta-lactamase enzymes [70,78]. However, 
the majority of clinical Staphylococcal infections are caused by strains producing β-
lactamases, so that benzylpenicillin has no further interest in the treatment of such infections 
[70]. Nevertheless, there are still situations in which the benzylpenicillin continues to be 
used as a drug of choice [70]. 
 
 
2.1.2. Aminopenicillins  
 
The aminopenicillins including amoxicillin, ampicillin and bacampicillin [71]. These 
aminopenicillins have an additional hydrophilic groups and are particularly effective against 
gram-negative bacteria that not produce β-lactamases [92]. However, your spectrum of 
action may include some gram-positive bacteria. The differences from penicillin are the 
presence of an amino group. That amino group helps the drug penetrate the outer membrane 
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of gram (-) bacterium [92]. Ampicillin acts as a competitive inhibitor of the enzyme 
transpeptidase, which is needed by bacteria to make their cell walls. It inhibits the third and 
final stage of bacterial cell wall synthesis in binary fission, which ultimately leads to cell 
lysis [70]. 
 
 
2.2. Chloramphenicol 
 
 
Chloramphenicol is an antibiotic produced synthetically, which acts by inhibition of 
bacterial protein synthesis. Chloramphenicol binds reversibly to the 50S ribosomal subunit 
and preventing binding of end of the tRNA, and therefore bacterial protein synthesis. 
Chloramphenicol has a very broad spectrum of action and it is mainly bacteriostatic, acts 
against most bacteria except the Mycobacteriaciae, Treponema and Actinomyces [93]. 
Furthermore, this antibiotic is ineffective against viruses, fungi and protozoa. 
 
 
2.3. Aminoglycosides 
 
 
Aminoglycoside antibiotics comprising a set formed of two or more amino sugars 
joined by a glycosidic linkage to a hexose aminated. Most of aminoglycosides have a natural 
origin. However, amikacin and gentamicin are two exceptions to the extent they are 
respectively semisynthetic derivative of sisomicin and kanamycin [94]. The kanamycin was 
formerly used in the treatment of severe infections caused by Gram-negative, but currently 
this antibiotic has low clinical use. Aminoglycosides act by interfering with protein synthesis 
and have a bactericidal effect (and not bacteriostatic effect, as all the other inhibitors of 
protein synthesis) [95]. The antibacterial spectrum of these antibiotics is quite extensive, 
including gram-negative bacteria, gram-positive and bacteria do not stain the Gram (such as 
the Koch's bacillus). In turn, the obligatory and facultative anaerobes are resistant to the 
action of aminoglycosides [94]. 
S. aureus and epidermidis are sensitive to aminoglycosides, whether or not produce 
β-lactamase. However, Staphylococcus quickly develop resistance against aminoglycosides. 
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Aminoglycosides are generally used in combination with other classes of antibiotics which 
have a synergistic effect between these antibiotics, especially the β-lactam [95]. 
 
 
2.4. Tetracycline 
 
 
Tetracyclines act by blocking bacterial protein synthesis, bind to the 30S ribosome 
subunit, preventing the aminoacyl tRNA binding to ribosomal receptor, and thus the growth 
of the peptide chain [96]. The effect of tetracyclines on the bacteria is reversible, such that, 
upon interruption of their use, the non-return eliminated microorganisms to multiply [97]. 
Tetracyclines are antibiotics with broad-spectrum action, with bacteriostatic action 
against various gram-positive and gram-negative and bacteria that not stain the Gram 
(including mycoplasmas, chlamydiae, rickettsiae) and some protozoans [97,98]. 
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Table 5 – Some of antibiotics used to treat bacterial infections by Staphylococcus aureus (EUCAST- European Committee on Antimicrobial Susceptibility Testing 
2016) [99]. 
 
Class/Antibiotics 
 
Mechanism of 
action 
Effect on bacteria Spectrum 
Penicillins 
 
Penicillin G 
 
Interfer with bacterial 
cell wall synthesis 
 
Bactericidal 
Active against non β-lactamase–producing gram (+) cocci 
(Pneumococci, Staphylococci, Streptococci), few gram (-) cocci 
(meningococci andgonococci), gram (+) bacilli (Bacillus anthracis, Bacillus 
erfringens, Bacillus diphtheriae) and anaerobes (Clostridum perfringens, C. 
tetani). 
Aminopenicillins 
 
Ampicillin 
Inhibitor of cell wall 
synthesis 
 
Bactericidal 
Aminopenicillins are similar to penicillin G in the activity against Gram (+) 
organisms but are slightly weaker than the latter. Aminopenicillins are more 
active against enterococci and Listeria monocytogenes compared to 
penicillin G. Gram (-) spectrum incudes Haemophilus 
influenza, Salmonella, Shigella, Escherichia coli, Proteus mirabilis, N. 
gonorrhoeae, N. meningitidis. 
Chloramphenicol 
 
Chloramphenicol 
Inhibition of bacterial 
protein synthesis 
Bacteriostatic 
Among the bacteria more sensitive are H. influenzae, N. meningitidis, N. 
gonorrhoeae, Salmonella typhi, Brucella, Bordetella pertussis, Streptococcus 
pyogenes, Streptococcus pneumoniae and anaerobic bacteria (Clostridium 
and Bacteroides fragilis), Staphylococcus aureus and some 
Enterobacteriaceae (such as E. coli, Proteus mirabilis, Shigella, 
Pseudomonas pseudomallei, Klebsiella, and some strains of Enterobacter 
and Serratia). 
Aminoglycosides 
 
Kanamycin 
Inhibition of bacterial 
protein synthesis 
Bactericidal 
Aminoglycosides have high activity against aerobic gram (-) bacilli (E. coli, 
Proteus, Klebsiella, Enterobacter, Salmonella, Shigella and Pseudomonas 
aeruginosa), Staphylococcus aureus and epidermidis. 
Tetracycline 
 
Tetracycline 
Inhibition of bacterial 
protein synthesis 
Bacteriostatic 
Action against various gram (+) and gram (-) such as Staphylococci, 
Enterococci, Pneumococci, Gonococci, some Enterobacteriaceae (such as 
Salmonella and Shigella), bacteria that not stain the Gram (including 
mycoplasmas, chlamydiae, rickettsiae) and some protozoans. 
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2.5. Microbial resistance 
 
The rapidly increasing emergence of antibiotic resistance amongst pathogenic 
bacteria assume increasing economic and social impact due to the high morbidity and 
mortality induced by the proliferation of antimicrobial resistance [78,80]. Bacteria replicate 
very rapidly and a mutation that helps a microbe to survive in the presence of an antibiotic 
drug will quickly become predominant throughout the microbial population [28,100]. The 
inappropriate prescription of antibiotics and the failure of some patients to complete their 
treatment regimen also exacerbate the problem [101]. 
The intended modes of action of antibiotics may be counter-acted by bacterial 
organisms via several different means [102]. This may involve preventing antibiotic access 
into the bacterial cell or perhaps removal or even degradation of the active component of the 
antimicrobial agent [78,103]. In fact, several different mechanisms may work together to 
confer resistance to a single antimicrobial agent [88]. Some of this mechanisms are described 
below: 
 Intrinsic Resistance 
Intrinsic resistance is the innate ability of a bacterial species to resist activity of a 
particular antimicrobial agent through its inherent structural or functional characteristics, 
which allow tolerance of a particular drug or antimicrobial class [88,104]. 
 Acquired Resistance 
Acquired resistance is said to occur when a particular microorganism obtains the 
ability to resist the activity of a particular antimicrobial agent to which it was previously 
susceptible [89,105]. This can result from the mutation of genes involved in normal 
physiological processes and cellular structures, from the acquisition of foreign resistance 
genes through a small circular DNA (plasmids) or from a combination of these two 
mechanisms [103,106]. 
Acquired resistance results from successful gene change and/or exchange that may 
involve: mutation or horizontal gene transfer via transformation, transduction or conjugation 
[89,102] described in Table 6. 
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Table 6 – Mechanisms that envolve the acquired resistance. 
Mechanism Description 
Transformation 
Involves uptake of short fragments of naked DNA by naturally 
transformable bacteria [103]. 
Transduction 
Involves transfer of DNA from one bacterium into another via 
bacteriophages [107]. 
Conjugation 
Involves transfer of DNA via sexual pilus and requires cell–to-cell 
contact. DNA fragments that contain resistance genes from resistant 
donors can then make previously susceptible bacteria express 
resistance as coded by these newly acquired resistance genes 
[89,102]. 
 
 Mutation 
A mutation is a spontaneous change in the DNA sequence within the gene that may 
lead to a change in the trait which it codes for [104,106]. Any change in a single base pair 
may lead to a corresponding change in one or more of the amino acids for which it codes, 
which can then change the enzyme or cell structure that consequently changes the affinity or 
effective activity of the targeted antimicrobials [102,105]. 
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CHAPTER 2 
 
Combining Antibiotics and Photodynamic Therapy to Inactivate 
Staphylococcus aureus on skin 
 
1. Introduction 
 
Staphylococcus aureus belongs to the natural microflora, resides on the surface of 
the skin and on mucous membranes of warm-blooded animals (present in the nose of about 
30% of healthy adults and on the skin of about 20%, and at higher percentages in patients 
admitted to hospitals and people who work there), but it may become pathogenic in 
conditions such as breakage of the skin barrier or decreased immunity [74,108–110]. Is a 
common Gram-positive bacteria that is responsible for a wide variety of disorders, causing 
wound infections and colonize the mucous of nasal cavity and normal skin of healthy 
population [110,111]. 
Its pathogenesis is dependent on the secretion of an array of virulence factors, the 
surface exposure of multiple cell wall anchored proteins [74] and extracellular components 
that are expressed during the different stages of infection: colonization, avoidance or 
invasion of the host immune defense, growth and cellular division culminating in bacterial 
dissemination, causing toxic effects to the host [112,113]. 
S. aureus infections are common in skin, but the bacterium can spread through the 
bloodstream and infect distant organs. As the bacterium tends to infect the skin, often 
causing abscesses [79], but as the bacterium can travel through the bloodstream, causing 
bacteremia and infect almost any site in the body, particularly heart valves (endocarditis) 
and bones (osteomyelitis) [76,114]. The bacterium also tend to accumulate on medical 
devices in the body, such as heart pacemakers, and catheters inserted through the skin into 
blood vessels [76]. 
These infections are usually treated with antibiotics that are chosen based on whether 
they are likely to be effective against the strain causing the infection. The penicillin, 
aminopenicillins, cephalosporin, aminoglycoside, tetracyclines and chloramphenicol are 
effective antibiotics to combat infection by S. aureus. However, both community-associated 
and hospital-acquired infections with S. aureus have increased in the past three decades, and 
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the rise in incidence has been accompanied by a rise in antibiotic-resistant strains [24,101], 
particularly methicillin-resistant S aureus (MRSA) and vancomycin-resistant strains 
(VRSA) [115,116] which are collectively recognized as a very serious health threat [8,80]. 
The resistance to penicillin emerged in the mid-1940s, only a few years after the introduction 
of this antibiotic in the clinical practice [101]. Later, in 1959, the semi-synthetic antibiotic 
methicillin was introduced for the treatment of infections caused by penicillin-resistant S. 
aureus [80]. Yet, in 1961 the first cases of methicillin- resistant S. aureus (MRSA) isolates 
[24] were reported and currently, only few compounds are still effective in the treatment of 
MRSA infections [101]. Vancomycin, the ‘‘drug of last resort’’has been the most reliable 
therapeutic agent against infections caused by meticillin-resistant S. aureus (MRSA). 
However, in 1996 the first MRSA to acquire resistance to vancomycin, was isolated from a 
Japanese patient. Subsequent isolation of several vancomycin resistant S. aureus (VRSA) 
strains from USA, France, Korea, South Africa, and Brazil has confirmed that emergence of 
vancomycin resistance in S. aureus is a global issue [70,79]. This resistance comes from the 
bacterial gene mutation and horizontal transfer of resistance genes from external sources 
[117,118].  
Although the intensive overuse of antimicrobial drugs began to exert new survival 
pressure on relevant microorganisms, antibacterial resistance was hardly acknowledged in 
the past as novel antibiotics became steadily available and were readily modified and 
improved for clinical use [24,101,117]. The development of novel but still conventional 
antibiotics, is not likely to solve the problem as it is probably only a matter of time until they 
will also ineffective. Bacterial resistance is undoubtedly recognized as a major medical 
challenge in most healthcare systems. Consequently, the traditional treatment of bacterial 
infections with antibiotics can be difficult, emphasizing the importance and urgency to 
develop new alternative treatments to treat bacterial infections. In this sense, new alternative 
therapies such as antimicrobial photodynamic therapy (aPDT) have been proposed. 
aPDT is being actively studied as a possible alternative to antibiotic treatment as in 
localized infections [60,64,119]. aPDT involves the combination of light, oxygen and PS 
that trust be able to produce ROS upon irradiation with light. Thus, when the dye absorbs a 
photon, an electron is promoted from its ground state to an electronically excited state that 
returns the energy. Although originally employed in the treatment of cancer during the last 
decade, an increasing number of studies on PDT application have been published about 
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microbiocidal effect in addition to better access to sites that are inaccessible to conventional 
therapy [120]. This technology has already shown to be effective against Gram-positive and 
Gram-negative bacteria, viruses, fungi, and parasites [64,119,121]. The major advantage of 
this technology over antibiotics is  the multi-target action [122] and no emergence of 
resistances [28,81,123]. 
Although it is well known that the use of large amounts of antibiotics in clinical 
practice is undesirable, since they give rise to the selection of antibiotic-resistant strains, 
little effort has been made to employ aPDT in order to increase the efficacy of such 
antibiotics, as well as to employ antibiotics to potentiate the efficacy of aPDT. Xing et al. 
(2011) tested a vancomycin-porphyrin conjugate to inactivate vancomycin-resistant 
enterococci, showing strong PDI activity of the conjugate against vancomycin-sensitive and 
resistant strains, when compared to vancomycin and porphyrin alone [124]. The combination 
of vancomycin with PDI was also useful in the disruption of S. aureus biofilms. Pre-treating 
the biofilms with PDI and then apply vancomycin at concentrations bellow the biofilm 
inhibitory concentration, causes a disintegration of the biofilm matrix and allows the killing 
of bacteria almost entirely [27]. Malik and Nitzan (1995) tested also the combination of 
different natural porphyrin derivatives and antibiotics (methicillin, ampicillin, polymyxin B 
nonapeptide, tetracycline) to inactivate both multi-resistant Gram-positive (S. aureus) and 
Gram-negative bacteria (E. coli) [125]. The photoinactivation of four multidrug resistant 
bacteria by a porphyrin derivative in the presence of ampicillin and chloramphenicol was 
also evaluated and the results showed that in the presence of porphyrins and antibiotics the 
bacterial photoinactivation was higher than when the porphyrin derivatives were used alone 
[49]. 
The aim of this study was to evaluate the antimicrobial applicability of aPDT to treat 
skin infections by S. aureus. Besides, the synergism of the combination of this therapy with 
conventional antibiotics was also studied. 
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2. Methods 
 
2.1.  Photosensitizer 
 
The PS applied in this study was a tetracationic porphyrin, the 5,10,15,20-
tetrakis(1-methylpiridinium-4-yl)porphyrin tetra-iodide (Tetra-Py+-Me) and was 
synthetized according to previously described procedure [126]. A stock solution of this 
porphyrin, at 500 µM, was prepared in dimethyl sulfoxide and stored in the dark. Before 
each assay the porphyrin solution was sonicated during 30 min at room temperature 
(ultrasonic bath 0.6L | Nahita). 
 
2.2.  Bacterial strains and growth conditions  
The strain of S. aureus (ATCC 6538) was inoculated on solid medium BD Baird-
Parker Agar (BPA)(Liofilchem) at 37 ºC during 24 h and posteriorly kept a 4 ºC (Work 
Sample). The bacterium was inoculated whenever necessary in liquid medium Brain-Heart 
Infusion (BHI) (Liofilchem) and grown aerobically at 37 ºC for 24 h under stirring (130 
rpm). For each assay, an aliquot of this culture (300 μL) was transferred twice into a new 
fresh BHI medium (subcultured in 30 mL) and grew overnight at 37 °C under stirring. 
2.3.  Irradiation conditions 
Following the dark incubation period (10 min for in vitro and 30 min for ex vivo), 
samples were exposed, in parallel, to white light: PAR radiation (13 OSRAM 21 lamps of 
18 W each, 380-700 nm) with an irradiance of 40 W m-2 or Lumacare system (an 
interchangeable fiber optic probe - 400–800 nm - coupled to a 250 W quartz/halogen lamp 
(LC-122; LumaCare, Newport Beach, CA, USA) with an irradiance of 150 W m-2, at 25 °C 
for 180 - 270 min.  
 
2.4.  Photoinactivation assays in PBS 
 Overnight bacterial cultures, were tenfold diluted in phosphate-buffered saline (PBS) 
to a final concentration of ~107-8 CFU mL-1 (colony-forming unit per mililitre). The diluted 
bacterial suspensions were distributed in 50 mL beakers (final volume of 10 mL per beaker) 
and incubated in the dark for 10 min at room temperature under 100 rpm stirring with 5.0 
μM of porphyrin (Tetra-Py+-Me), to promote the PS binding to cells. Then the beakers are 
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irradiated by white light with an irradiance of 40 W m-2. Bacterial suspensions were 
irradiated up to 270 min (total light dose of 64.8 J cm-2) and sub-samples of 100 µL were 
collected at the beginning of the irradiation (time 0) and after 15, 30, 60, 90, 180 and 270 
min of exposure to light. After each photosensitization period, the cells were serially diluted 
in PBS, pour-plated in solid medium trypticase soy agar (TSA) (Liofilchem) and incubated 
at 37 °C for 24 h, for viability monitoring. The cell viability was determined by counting the 
CFU mL-1 on the most appropriate dilution. Control samples were included in all PDI 
experiments: light control (LC) consisted of a bacterial suspension that was exposed to light; 
and dark control (DC) consisted of a bacterial suspension incubated with PS at the maximum 
concentration under the same conditions as the samples, but protected from light. Three 
independent experiments were conducted. 
 
2.5.  Photoinactivation assays in PBS combined with antibiotics 
In these assays, the photoinactivation of S. aureus with the PS at 5.0 µM in the 
presence of five antibiotics: ampicillin (Applichen Panreae), chloramphenicol (Applichen 
Panreae), Kanamycin (Applichen Panreae), Penicillin G (Sigma Life-Science) and 
Tetracycline (Sigma Life-Science) was evaluated. All the antibiotics were tested at the 
minimum inhibitory concentrations (MIC) according EUCAST- European Committee on 
Antimicrobial Susceptibility Testing (2016) and accordingly to the Clinical and Laboratory 
Standards Institute [CLSI] (2013) [99,127]. The MIC concentrations were, 0.25 μg mL-1, 8 
μg mL-1, 2 μg mL-1, 0.125 μg mL-1 and 1.0 μg mL-1, respectively, for ampicillin, 
chloramphenicol, kanamycin, penicillin G and tetracycline. For ampicillin two more 
concentrations were tested 0.5 μg mL-1 and 1.0 μg mL-1. 
 
For each assay four goblets of 50 mL were prepared: one with bacteria diluted 1:10 
in PBS and PS (Sample); other with bacteria diluted 1:10 in PBS and PS, plus antibiotic (PS 
+ (abbreviation of the used antibiotic)); other with bacteria diluted 1:10 in PBS and antibiotic 
(Antibiotic Control - AC); other with bacteria diluted 1:10 in PBS and PS, which was kept 
in dark conditions, wrapped in aluminium foils (DC) and other with bacteria diluted 1:10 in 
PBS (LC). The quantity of antibiotic was the same used in the Sample and in the Antibiotic 
Control. The goblets were kept under irradiation 180 min and aliquots were taken at 0, 15, 
30, 60, 90 and 180 min. The aliquots were diluted in PBS and plated in TSA by 
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incorporation. After 24 h at 37 ºC, the number of colonies was enumerated and the results 
were expressed in CFU mL-1. For each assay was done three independent experiments in 
duplicates. 
Before aPDT assays the susceptibility of the S. aureus strain to the used antibiotics 
was evaluated using the Disk Diffusion Test. Overnight bacterial cultures in liquid medium 
BHI, growth at 37 °C, was diluted 1:100 in saline solution until a turbidity compatible with 
the 0.5 standard of MacFarland (1x106 CFU/mL) [128]. With a sterile swab was seeded on 
the surface of Mueller Hinton agar (MHA) in Petri plates. Then the discs were placed on the 
plates which were incubated posteriorly at 37 °C for 24 h. The sensitivity was determined 
by measuring the halo of growth inhibition diameter and compared with the zone diameter 
breakpoint established by EUCAST- European Committee on Antimicrobial Susceptibility 
Testing (2016) and accordingly to the Clinical and Laboratory Standards Institute [CLSI] 
(2013) [99,127]. 
 
2.6.  Photoinactivation assays in skin model (ex vivo) 
Its performed assays of aPDT in pocine skin with a porphyrin (Tetra-Py+-Me) in 
different conditions. 
 
2.6.1.  Preparation of porcine skin 
Fresh skin of porcine was obtained from a local gash. The skin was cut into four 
portions of area 10 cm2 (5 x 2 cm) pieces (one of them used as test sample and three as 
controls) and the adipose tissue beneath the dermis was removed with a scalpel. The excised 
skin was placed in a sterile Petri dish and disinfected with 70% ethanol, washed with sterile 
PBS and placed under ultraviolet radiation for 30 min. 
After, an aliquot of 500 μL of an overnight culture of S. aureus diluted in PBS (1:10) 
was distributed over the three skin pieces using an aerosol spray to obtain a density of 
approximately 105 CFU per cm2. An aliquot of 500 μL of PS diluted in PBS (final 
concentration 25 μM, 40 μM or 50 μM) was sprayed on two of the skin portions (Sample 
and DC). The other skin portion (LC) was sprayed with 500 μL of PBS to ensure the same 
volume sprayed into the others skin pieces. The fourth skin portion (Bacterial Control - BC) 
was not contaminated with S. aureus, because was used as control to verify the efficiency of 
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the skin disinfecting to inactivate resident bacteria present in the skin, and then sprayed with 
1000 μL of PBS to ensure the same volume condition. 
All skin portions were covered with aluminum paper and incubated for 30 min in 
dark, to promote the PS binding to skin cells. The porcine skin samples were irradiated with 
two different white light conditions with irradiances of 40 W m-2 and 150 W m-2. The dark 
control must be covered with aluminum paper. After irradiation, a sterile cotton wool swab 
was used to remove the bacteria from each skin portion after 0, 60, 90, 120 and 180 min. 
The cotton wool swab was moistened in PBS before swabbing the skin surface. The cotton 
wool swab was passed on each skin piece 30 times. The bacteria present in the cotton wool 
swab were suspended in 2.0 mL of PBS diluted in PBS, pour-plated in solid medium TSA. 
The plates were incubated at 37 °C for 24 h, for viability monitoring. The cell viability was 
determined by counting the CFU on the most appropriate dilution. Three independent 
experiments were conducted in duplicate.  
 
 
 
2.7.  Photoinactivation assays combined with antibiotic in the skin model (ex vivo) 
 
The same previously described protocol, including two more samples: antibiotic 
control (AC) and PS with antibiotic (PS+antibiotic), was used. In these experiments, only 
ampicillin was used at 1.0 μg mL-1 and 5 μg mL-1. The PS was tested at 40 μM or 50 μM 
under white light irradiance of 150 W m-2.  
 
2.8.  Statistical Analysis 
 
Statistical analyses were performed using GraphPad® Prism 6.01. Normal 
distributions were assessed by the same software. The significance of a Tetra-Py+-Me and 
irradiation time on bacterial was assessed by two-way ANOVA analysis of variance. 
Morover, when the significance was accepted, at (p < 0.05), Tukey´s multiple comparison 
test was used for a pairwise comparison of the means. Three independent experiments were 
conducted in duplicate for each assay.  
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3. Results 
 
 
The clinical strain employed in this study, the S. aureus (ATCC 6538) is susceptible 
to all tested antibiotics (Figue 4), ampicillin, chloramphenicol, kanamycin, penicillin G and 
tetracycline. 
 
Antibiotics 
Standards zone 
diameter 
breakpoint 
(mm) 
Results of 
diameter 
breakpoint 
(mm) 
 
Images 
S ≥ R < 
Ampicillin 29 28 32 
 
Penicillin G 26 26 40 
Kanamycin 18 13 26 
Chloramphenicol 18 18 20 
 
Tetracycline 22 19 21 
 
Figure 4 – Drug-resistance profile to antibiotics for the studied strain. 
 
 
 
3.1. Photoinactivation of bacteria in PBS  
 
 
The aPDT with 5.0 µM of Tetra-Py+-Me and an irradiance of 40 W m-2 was effective 
against S. aureus in PBS, leading to a reduction in colony forming units (CFU) of 8.0 log, 
after 180 min of irradiation (Figue 5). Light controls and dark controls results show that the 
viability of S. aureus is not affected by irradiation itself nor by the PS used in the dark at the 
concentration of 5.0 μM (7-8 log CFU/mL maintained during all irradiation period) 
(ANOVA, p > 0.05).  
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Figure 5 - Photoinactivation of S. aureus (ATCC 6538) in PBS, after 30, 60, 90 and 180 min, incubated 
with Tetra-Py+-Me at 5.0 µM and irradiated with white light at an irradiance of 40 W m-2 (PS, 
Photosensitizer; LC, Light Control; DC, Dark Control). Three independent assays were done. Each value 
corresponds to the mean ± standard deviation of two replicates. Error bars correspond to standard 
deviations. 
 
 
 
3.2.  Photoinactivation of bacteria by aPDT and antibiotics in PBS 
 
When the aPDT assays were performed in the presence of antibiotic, changes on the 
incativatiom profile was observed. Thus, when the ampicillin was added to the bacterial 
suspension and the aPDT treatment performed an increase in the efficiency of inactivation 
was observed for the two highest ampicillin concentrations (0.5 µM and 1.0 µM). The 
photoinactivation with 5.0 μM of Tetra-Py+-Me in combination with ampicillin at MIC 
concentration (0.25 μg mL-1) showed the same bacterial reduction (ANOVA, p > 0.05) 
observed when only PS was used (Figure 6 A).  
When the concentration of ampicillin was increase to 0.5 μg mL-1 (Figure 6 B) the 
photoinactivation occurred earlier, showing a reduction of ~8 log after 60 min of irradiation. 
When ampicillin was used at 1.0 μg mL-1, the aPDT efficiency increase still observed, either 
relatively to S. aureus photoinactivation without the presence of antibiotic nor to the other 
two antibiotic tested concentrations (ANOVA, p < 0.05). A reduction of ~ 8 log was achieved 
after 30 min of irradiation (Figure 6 C). The antibiotic controls at different concentrations of 
ampicillin (0.25 μg mL-1, 0.5 μg mL-1 and 1.0 μg mL-1) showed that the viability of S. aureus 
0
2
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was not affected by its presence (7 - 8 log CFU mL-1) maintained the cell viability during all 
irradiation period (ANOVA, p > 0.05).  
 
 
 
 
The aPDT treatment with Tetra-Py+-Me at 5.0 μM combined with chloramphenicol 
at 8.0 μg mL-1, point out an efficiency decrease of bacterial inactivation (1.7 log) when 
compared with the photoinactivation without the presence of chloramphenicol in the early 
inactivation times (after 60 min, ANOVA, p < 0.05), but for the others tested periods the S. 
aureus photoinactivation was similar in both samples conditions (ANOVA, p > 0.05) (Figure 
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Figure 6 - Photoinactivation of S. aureus in 
PBS, after 30, 60, 90 and 180 min of irradiation 
at 40 W m-2, at 5.0 µM of Tetra-Py+-Me and 
ampicillin concentrations of 0.25 μg mL-1 (A), 
0.5 μg mL-1 (B), 1.0 μg mL-1 (C) (PS, 
Photosensitizer; PS + Amp, Photosensitizer with 
ampicillin; LC, Light Control; DC, Dark Control; 
AC, ampicillin and light). Three independent 
assays were done, in which each value 
corresponds to the mean ± standard deviation of 
two replicates. Error bars correspond to standard 
deviations. 
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7 A). The chloramphenicol alone (AC) (Figure 7 A) does not reduce the S. aureus abundance, 
which it was kept constant throughout the assay (ANOVA, p > 0.05).  
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Figure 7 - Photoinactivation of S. aureus in PBS, after 30, 60, 90 and 180 min of irradiation at 40 W 
m-2 with a concentration 5.0 µM of Tetra-Py+-Me and chloramphenicol concentrations of 8.0 μg mL-
1 (A), Kanamycin 2.0 μg mL-1 (B), Penicillin G 0.125 μg mL-1 (C) and Tetracycline 1.0 μg mL-1 (D) 
(PS, Photosensitizer; PS + CHLOR, Photosensitizer with Chloramphenicol; PS + KAN, Photosensitizer with 
Kanamycin; PS + PEN G, Photosensitizer with Penicillin G; PS + TETRAC, Photosensitizer with 
Tetracycline; LC, Light Control; DC, Dark Control; AC, control of the antibiotic-different in each graph). 
Three independent assays were done, in which each value corresponds to the mean ± standard deviation of 
two replicates. Error bars correspond to standard deviations. 
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For aPDT treatment associated with kanamycin at 2 μg mL-1 (Figure 7 B), the 
bacterial reduction after 60 min and 90 min of irradiation was more effective (~1.9 log) than 
that observed when aPDT was done without antibiotic (ANOVA, p < 0.05). However, after 
180 min the two samples reached the same bacterial inactivation (8 log) (ANOVA, p > 0.05). 
A small reduction of 0.6 log in bacterial concentration was observed after 180 min relatively 
to the bacterial control (ANOVA, p<0.05). The aPDT treatment in the presence of penicillin 
G at 0.125 μg mL-1 showed significant difference (ANOVA, p < 0.05) relatively to the 
inactivation without antibiotic (Figure 7 C) after 30 min of irradiaton (~2 log), although the 
results remained similar in both samples at longer times (ANOVA, p > 0.05). The penicillin 
G alone does not affect the the S. aureus abundance during the assay, the concentration 
remained constant in all assay (7-8 log) (ANOVA, p> 0.05). 
No significant differences were observed between aPDT in combination with 
tetracycline at 1.0 μg mL-1 and aPDT alone (Figure 7 D) (ANOVA, p > 0.05). The 
tetracycline alone reduced S. aureus by ~0.7 log relatively to the bacterial control after 180 
min. (ANOVA, p > 0.05). 
 
 
3.3.  Influence of light source on photoinactivation on porcine skin 
 
 
Both white lights, 40 W m-2 and 150 W m-2, were effective to inactivate the 
bacterium, but light with the irradiance of 150 W m-2 causeda higher reduction. Also a 
significant difference between PS concentrations (25 µM and 50 µM) was observe under 
both light sources.  
Tetra-Py+-Me at 25 µM under irradiation at 40 W m-2 does not inactivate S. aureus, 
the concentration remained constant, about 5 log during the 180 min of irradiation (Figure 8 
A). However, increasing the concentration to 50 µM, a reduction of 0.8 log was observed 
after 90 min (Figure 8 A). The differences between the two concentrations were significant 
after 60 min of irradiation (ANOVA, p < 0.05). No statistical difference for DC and LC was 
observed during the assay (ANOVA, p > 0.05).  
When irradiation was done at an irradiance of 150 W m-2 (Figure 8 B) at 25 µM of 
Tetra-Py+-Me, a reduction of S. aureus of about ~ 0.5 log was observed after 180 min of 
irradiation, but the difference relatively to the bacterial control was not significant (ANOVA, 
p > 0.05). 
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Increasing the concentration of Tetra-Py+-Me to 50 µM and using an irradiance of 
150 W m-2, a decrease of about 4 log was observed after 180 min of irradiation (Figure 8 B). 
In this condition, bacterial concentrations were significantly different from that observed in 
the bacterial control afterafter 30 min until the end (ANOVA, p < 0.05). Light and dark 
controls showed no significant differences inthe viability of S. aureus (~5 log CFU/mL 
maintained during all irradiation period) (ANOVA, p > 0.05) (Figure 8 B). 
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Figure 8 – (A) Photoinactivation of S. aureus on porcine skin, after 60, 90 and 180 min of irradiation 
at 40 W m-2 (PS 25, Photosensitizer with Tetra-Py+-Me in 25 µM; PS 50, Photosensitizer with Tetra-Py+-
Me in 50 µM; LC, Light Control; DC, Dark Control). (B) Photoinactivation of S. aureus on porcine skin, 
after 60, 90, 120 and 180 min of irradiation at 150 W m-2 (PS 25, Photosensitizer with Tetra-Py+-Me in 
25 µM; PS 50, Photosensitizer with Tetra-Py+-Me in 50 µM; LC, Light Control; DC, Dark Control). Three 
independent assays were done, in which each value corresponds to the mean ± standard deviation of two 
replicates. Error bars correspond to standard deviations. 
 
 
 
 
3.4. Photoinactivation of bacteria by aPDT and antibiotic in porcine skin 
 
The combination of aPDT and ampicillin on porcine skin was tested under 150 W m-2 
with 50 µM or 40 µM of PS and 1.0 μg mL-1 and 5 μg mL-1 of antibiotic. 
The photoinactivation at 50 μM of Tetra-Py+-Me in the presence of ampicillin at 5 μg 
mL-1) showing a reduction of ~5.6 log after 180 min of irradiation (Figure 9). When the 
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antibiotic was not added after at 180 min of irradiation, a reduction of ~4 log was observed.  
In the conditions of this antibiotic concentration, a reduction of ~1 log of S. aureus was 
observed after 120 min. The viability of S. aureus in light and dark controls was not affected 
(ANOVA, p > 0.05) (Figure 9). 
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Figure 9 - Photoinactivation of S. aureus on porcine skin, after 60, 90, 120 and 180 min of irradiation 
at 150 W m-2 with a concentration 50 µM of Tetra-Py+-Me and ampicillin in concentrations of 5 μg 
mL-1 (PS, Photosensitizer; PS + AMP, Photosensitizer with Ampicillin; LC, Light Control; DC, Dark 
Control). Two independent assays were done, in which each value corresponds to the mean ± standard 
deviation of two replicates. Error bars correspond to standard deviations 
 
Reducing the concentration of Tetra-Py+-Me to 40 μM in the presence of ampicillin at 
1 μg mL-1 the bacterial reduction observed was similar to that observed when the antibiotic 
was not added (ANOVA, p > 0.05) (Figure 10 A). After at 180 min of irradiation, a reduction 
of ~ 99,99% (4 log) was observed for both aPDT and aPDT plus ampicillin (1.0 μg mL-1). 
Only the antibiotic at this concentration, reduced ~0.5 log of S. aureus was observed after 
180 min. The viability of S. aureus in light and dark controls was not affected (ANOVA, p 
> 0.05) (Figure 10 A).  
Increasing the concentration of ampicillin to 5 μg mL-1, in same conditions, the 
inactivation was also similar to that of aPDT without antibiotic addition (ANOVA, p > 0.05) 
(Figure 10 B).  A reduction of of 4 log was observed for both samples after 180 min of 
irradiation (ANOVA, p > 0.05). Nevertheless, at this antibiotic concentration, a reduction of 
~1 log of S. aureus was observed after 120 min. Bacterial concentration in both light and 
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dark controls was constant during all the irradiation period (ANOVA, p > 0.05) (Figure 10 
B). 
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Figure 10 - Photoinactivation of S. aureus on porcine skin, after 60, 90, 120 and 180 min of irradiation 
at 150 W m-2 with a concentration 40 µM of Tetra-Py+-Me and ampicillin in concentrations of 1.0 μg 
mL-1 (A), Ampicillin 5 μg mL-1 (B) (PS, Photosensitizer; PS + AMP, Photosensitizer with Ampicillin; LC, 
Light Control; DC, Dark Control). Three independent assays were done, in which each value corresponds 
to the mean ± standard deviation of two replicates. Error bars correspond to standard deviations 
 
 
3.5.  Photoinactivation of bacteria by aPDT in porcine skin after three cycles of 
treatment 
 
When three aPDT cycles of 180 min were applied with 50 µM of porphyrin under 150 
W m-2 in porcine skin, S. aureus was inactivated by 5.5 log, to the detection limit of the 
method. Bacterial concentration in light control was constant during all the irradiation period 
(ANOVA, p > 0.05) (Figure 11). 
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Figure 11- Photoinactivation of S. aureus on porcine skin, after three successive cycles of aPDT of 
180 min with an irradiation at 150 W m-2 with a concentration 50 µM of Tetra-Py+-Me (PS, 
Photosensitizer; LC, Light Control. Two independent assays were done, in which each value corresponds 
to the mean ± standard deviation of two replicates. Error bars correspond to standard deviations. 
 
 
3.6. Images of skin before and after treatment with aPDT 
 
At the naked eye, no negative effects on the porcine skin were observed after 180 min 
of aPDT treatment with 50 µM of porphyrin under 150 W m-2.  
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Figure 12 – Images of porcine skin before and after treatment with aPDT. (PS, Photosensitizer; LC, Light 
Control). 
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4. Discussion  
Regardless of the abundant literature about in vitro studies of aPDT against S. aureus 
as well as about in vivo assays of aPDT to treat S. aureus wound infections in mice 
[11,86,129] only a study described the ex vivo use of aPDT to treat S. aureus skin infections 
was done [84]. Moreover, no studies were done to demonstrate the potential of using aPDT 
combined with antibiotics against S. aureus to increase the efficiency of bacterial 
inactivation. 
In this study, an ex vivo porcine skin model was used to evaluate the aPDT efficacy 
against S. aureus. The results demonstrate that the inactivation of S. aureus by aPDT with a 
tetracationic porphyrin in vitro and ex vivo porcine skin model (1) was effective to inactivate 
S. aureus; (2) the efficacy of inactivation was concentration and light dose dependent; (3) 
the repetition of aPDT treatment increased significantly the bacterial inactivation; (4) the 
efficacy of S. aureus inactivation by aPDT in the presence of antibiotics increased 
significantly and that (5) this increase in aPDT efficacy was PS and antibiotic concentration 
dependent. 
In vitro experiments a high bacterial concentration, around of 108 CFU mL-1, which 
correspond to standard bacterial concentration used in other antimicrobial assays, such as 
antibiograms, was used and S. aureus was photoinactivated to the detection limit of the 
method (reduction of 8 log CFU) using a low PS concentration (5.0 µM) and a low irradiance 
(40 W m-2). After 60 min of treatment, a reduction of 5 log was already observed. Similar 
results were obtained for this PS using other bacteria, namely a MRSA strain, under similar 
experimental conditions [49]. 
In ex vivo experiments, a lower concentration of bacteria was used, around 106 CFU 
mL-1. As, in general, when bacteria are present in concentrations higher than 105 CFU mL-1 
is considered a human infection [130,131], the ex vivo bacterial concentration tested in this 
study correspond to a skin infection situation. In this case, the maximal bacterial reduction 
was 4 log CFU, but a much higher PS concentration (50 µM) and irradiance (150 W m-2) 
were necessary. The maximal of bacterial inactivation was higher than the 3 log CFU 
reduction (killing efficiency of 99.9% or more) established by the American Society of 
Microbiology to any new approach to be termed “antibacterial” [132]. However, under the 
same conditions, but using the PS at 25 µM, no significant bacterial inactivation was 
observed (reduction below 0.5 CFU log). Also, under low light dose, 40 W m-2, no significant 
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bacterial inactivation was observed, even at 50 µM (reduction of around 1 CFU log). Overall, 
it was necessary to use a 10× fold higher concentrations and a 40x fold higher irradiance in 
this ex vivo model as compared to in vitro. Similar results were already observed by Maisch 
et al. (2007) [84]. These authors showed that a 100× fold higher concentration of a porphyrin 
derivative was sufficient to inactivate a MRSA strain in ex vivo porcine skin than in vitro. 
This is, however, expected because in vitro bacteria and PS are in solution, which allow that, 
at a given concentration, more PS molecules could bind to the surface of each bacterium 
resulting in a higher yield of ROS near the bacteria and therefore a higher antibacterial 
efficacy.  
In the ex vivo skin model, bacteria are trapped in the tissue and, consequently PS 
molecules do not bind so efficiently to the bacterial cells. Besides, the PS can also adsorb to 
skin cells, being by this way less PS available to inactivate the bacteria. In fact, it is well 
know that the efficiency of aPDT is lower in samples with high contents of organic matter 
or cells. Lasocki et al. (1999) studied the antibacterial photodynamic effect of a 
hematoporphyrin derivative using P. aeruginosa and S. aureus either as suspension cultures 
in nutrient broth or as colonies growing on isolated mouse muscles [133]. The antibacterial 
effect was 1000 times greater in the case of suspension cultures and the concentration of PS 
necessary for optimal effects was much lower. Moreover, light penetration is more difficult 
in skin than that observed in vitro, in the buffer solution, reducing also the ROS production. 
These results highlight the importance of testing the efficacy of aPDT to inactivate bacteria 
in clinically relevant setting, such as porcine skin, which has been proposed as a good test 
model for human skin. Porcine skin has similar histological, physiological and 
immunological properties to human skin and has been suggested as a good analogue for 
medical research [134,135]. 
Although a higher PS concentration and a higher light dose were used in ex vivo skin 
model compared to in vitro, S. aureus after a cycle of treatment was not completely 
inactivated. After one aPDT cycle of 180 min with 50 µM of porphyrin under 150 W m-2 in 
porcine skin, around 2 CFU log of bacteria survive. However, when more two cycles of 
aPDT was applied, S. aureus was inactivated to the detection limit of the method, the 
remained 2 CFU log of bacteria after the first cycle were efficiently inactivated after two 
more cycles of treatment. Similar results have been observed in other in vivo studies. For 
instance Souza, et al. (2014) showed that to treat by aPDT toenail onychomycosis with 
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methylene blue, several sessions with an interval of 15 days between each session for 6 
months, were done [136]. However, when antibiotics therapy is used to control bacterial 
infections and prevent relapse, several doses of antibiotics are administered. In general, 
antibiotic therapy has been conducted for 7 or 10 days with more than one dose by day. 
Nevertheless, it has been stated that longer exposure to antibiotics can contribute to 
resistance, causing also risks and harms for the patient [137–139]. But, if a person takes an 
inadequate course of antibiotics, they may relapse and require further treatment [140,141]. 
This increases the risk of developing resistance, as it would expose the person to antibiotics 
for longer. Conversely, the resistance problem does not arise for aPDT due to its mode of 
action and type of biochemical targets (multi-target process). So, the use of more than one 
treatment cycle to treat an infection could be a strong option. Moreover, in this study, it was 
only tested a series of 3 cycles of treatment and no viable bacteria were detected. Maybe 2 
cycles could be enough to control the bacterial growth on porcine skin model. 
Although the successful use of antibiotics is compromised by the potential 
development of resistance, their use is yet the first treatment option to treat and sometimes 
to eradicate diseases caused pathogenic bacteria such as S. aureus [28,78]. Now many of S. 
aureus strains are resistant to beta-lactams, macrolides, and even vancomycin, the ‘‘drug of 
last resort’’[70,79]. However, although it is well known that the use of these antibiotics give 
rise to the selection of antibiotic-resistant strains, avoiding bacterial inactivation, little effort 
has been made to employ aPDT in order to increase the efficacy of such antibiotics as well 
as to employ antibiotics to potentiate the aPDT efficacy. 
In this work aPDT was tested in vitro and ex vivo in the presence of five antibiotics 
(ampicillin, chloramphenicol, penicillin, kanamycin and tetracycline) used to treat bacterial 
infections by S. aureus [99,127]. From these, ampicillin and penicillin interfere with 
bacterial cell wall synthesis and the other three inhibit bacterial protein synthesis. 
Chloramphenicol and tetracycline are bacteriostatic and the other three are bactericidal. The 
results showed that at MIC concentration none of these antibiotics enhance the efficacy of 
aPDT. The efficiency of photoinactivation with and without antibiotics was similar. 
However, when the five antibiotics were tested alone, the bacterial concentration was not 
affected after 180 min, even when the bactericidal antibiotics were used. Nevertheless, when 
the susceptibility of bacteria to these antibiotics was tested using the susceptibility test discs 
method, the five disks showed large zones of inhibition, indicating that the S. aureus strain 
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is susceptible to the tested antibiotic. As the in vitro experiments were done in a buffer 
solution, a long incubation period would be necessary to observe decrease of bacterial 
concentration. Having into account these results, one of the antibiotics, the ampicillin, was 
tested at higher concentrations, corresponding to 2x and 4x the MIC in vitro and 4x and 20x 
the MIC ex vivo. The choice took into account the fact that this antibiotic is bactericidal and 
interferes with bacterial cell wall synthesis, which is a target of aPDT. Being the main target 
of aPDT the external structures of the bacteria [122], cell membrane and cell wall, are 
destabilized allowing an easier enter of the antibiotics into the bacterial cells. In fact, the 
efficacy of S. aureus inactivation increased when aPDT was done in the presence of 
ampicillin in vitro and ex vivo. 
In vitro, the synergistic effect was detected for the two antibiotic concentrations, but 
the photoinactivation in the presence of the higher concentration of ampicillin was observed 
sooner (reduction of 8 CFU log after 30 min of treatment) than with the lower concentration 
(reduction of 8 CFU log after 60 min of inactivation). When aPDT was done without the 
antibiotic, a similar bacterial reduction of 8 CFU log was obtained but only after 90 min of 
treatment. When the antibiotic was tested alone, no bacterial reduction was observed, even 
at the highest concentration, 1.0 µg mL-1. Similar results were observed using the same PS 
and antibiotic for MDR S. aureus, Escherichia coli, Acinetobacter baumannii and 
Pseudomonas aeruginosa [82] and using other PS using vancomycin for vancomycin-
sensitive and vancomycin-resistant enterococci [124] and methicillin, ampicillin, polymyxin 
B nonapeptide and tetracycline for both Gram-positive multi-resistant bacteria (S. aureus) 
and Gram-negative multi-resistant bacteria (E. coli) and for the disruption of S. aureus 
biofilms [27]. It is important to note that the synergistic effect of both therapies was only 
observed when aPDT alone cause a significant reduction in the bacterial concentration. For 
both antibiotic concentrations after 15 min of treatment, when no aPDT inactivation was still 
observed, no synergistic effect was detected, but after 30 min, when aPDT inactivation was 
already noticed, the synergistic effect was also observed. 
In ex vivo, a similar pattern of variation was observed but only for the highest 
concentrations (5 µg mL-1) of antibiotic. aPDT with antibiotic at 5 µg mL-1, bacterial 
concentration was reduced to the detection limit of the method (a reduction of 6 CFU log 
after 180 min). The reduction with aPDT alone in the same conditions was 4 CFU log after 
180 min of treatment. When the antibiotic was used alone, the maximal inactivation was of 
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1 CFU log after 180 min. At 1.0 µg mL-1, no synergistic effect was observed. As for the in 
vitro experiments, the synergistic effect of both therapies was only observed when aPDT 
inactivation was observed, that is, after 90 min of treatment. This indicate that, as the main 
target of aPDT are the external structures of the bacteria [122], cell membrane and cell wall, 
these structures are destabilized during aPDT allowing an easier enter of the antibiotics into 
the cells block internal processes (inhibiting for instance protein synthesis that can be the 
antibiotic target, like chloramphenicol) and, naturally, improving the action of antibiotics 
which have the external structures as its target (like ampicillin). By this way, a synergistic 
effect between aPDT and antibiotics can be observed. 
For low antibiotic and PS concentrations no synergistic effect was observed in the S. 
aureus inactivation. In vitro, an antibiotic concentration of 1.0 µg mL-1 (corresponding to 2x 
MIC) was necessary increase the efficacy of aPDT at 5.0 µM of PS. In ex vivo, a 
concentration of 5 µg mL-1 of ampicillin (corresponding to 20x MIC) and of 50 µM of PS 
was required to observe a synergistic effect in bacterial inactivation. Reducing the 
concentration of PS to 40 µM and maintaining the concentration of the antibiotic, no 
significant effect was observed relatively to aPDT without antibiotic. In the experiments 
with PS at 50 µM and PS 40 µM, the profile of aPDT inactivation without antibiotic was 
different in the first exposure times (60 min to 120 min), but at the end of the treatment the 
inactivation was similar. This different profile of inactivation was due to the use of different 
providers of porcine skin (in the experiments of irradiation at 150 W m-2 with a concentration 
50 µM of Tetra-Py+-Me and ampicillin in concentrations of 5 μg mL-1 a different provider 
of skin was used in the other experiments a same provider was used). 
The results suggest that both therapies can increase the efficacy of bacterial 
inactivation, allowing the reduction of porcine skin treatment time for a quarter, but the 
reduction in PS or antibiotic concentration avoid the synergistic effect of the two therapies. 
One aspect to be considered when aPDT is used to inactivate microorganisms in 
clinic is the selectivity of the PS for the microbes, avoiding an unacceptable degree of host 
tissue damage in the area of infection. With the exception of the prodrug 5-aminolevulinic 
acid (5-ALA), the precursor of protoporphyrin IX (PpIX), in situ and in vivo aPDT assays 
show that, in general, negative effects of PS on host cells do not occur when the PS is used 
at concentrations that are effective to microbial inactivation [142]. Furthermore, studies with 
the 5-ALA has shown that skin toxicity is the only relevant adverse effect known so far. 
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During light exposures, patients may experience pain in the irradiated region. Likewise, the 
time of incubation necessary for uptake and metabolism of the precursor and the long-lasting 
skin photosensitivity could be also other adverse effects of aPDT by 5-ALA [143]. In 
addition, the other antibacterial approaches, such as antibiotics application has also negative 
effects to the host. Nevertheless, porphyrins, such as the PS tested in this study, do not cause 
adverse effects on host cells [43]. Photodynamic inhibition of microorganisms occurs at 
porphyrin concentrations lower than those found to be cytotoxic for the host mammalian 
cells [43,144]. In fact, in this study, at the naked eye, no negative effects on the porcine skin 
were observed after 180 min of aPDT treatment with 50 µM of porphyrin under 150 W m-2, 
suggesting that the porcine skin is still vital. However, more physiological studies are needed 
in order to evaluate the safety of the aPDT developed protocol. It is also increasingly 
necessary to assess the safety of aPDT directly on skin in vivo. 
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5. Future perspectives 
After this work, it would be interesting to evaluate: 
 the effect of other PS on S. aureus inactivation, especially PS mixtures with 
different ROS production pathways, for example the conjugation of 
tetracationic porphyrin, which produce mainly singlet oxygen to methylene 
blue that, contrary to the porphyrin, produces essentially free radicals; 
 test the use of others antibiotics in sinergism with aPDT; 
 the efficacy of two successive aPDT cycles to inactivate S. aureus; 
 the efficacy of aPDT to inactivate methicillin-resistant S. aureus (MRSA) in 
skin model; 
 use of different light condition, like red light (625 a 740 nm), once it 
penetrates deeper into tissues; 
 the efficacy of aPDT to inactivate S. aureus “in vivo” (using an animal model 
the mouse). 
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